STOCK TITAN
  1. Home
  2. News
  3. YS

YS Biopharma Co Ltd - YS STOCK NEWS

Welcome to our dedicated news page for YS Biopharma Co (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect YS Biopharma Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of YS Biopharma Co's position in the market.

News
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
Rhea-AI Summary
YS Biopharma Co., Ltd. receives a requisition for an extraordinary general meeting from APEX Prospect Limited, a shareholder holding over 10% of voting power, to address alleged misconduct by the former chairperson. The Board agrees to convene the meeting on February 22, 2024, to vote on resolutions regarding governance and management changes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News
YS Biopharma Announces Appointment of New Directors
Rhea-AI Summary
YS Biopharma Co., Ltd. appoints six new members to its Board of Directors, including Dr. Yuntao Cui, Dr. Jin Wang, Mr. Henry Chen, Mr. Haitao Zhao, Mr. Pierson Yue Pan, and Ms. Brenda Chunyuan Wu. Dr. Ajit Shetty elected as Chairperson of the Board. The new directors bring expertise in law, finance, real estate, and biotech industries, enhancing the company's governance and strategic decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
management
-
News
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
Rhea-AI Summary
YS Biopharma Co., Ltd. issues an official response to the notice of an extraordinary general meeting of shareholders. The Convening Shareholders aim to remove six directors and appoint four new ones. The Company questions the validity of the EGM due to insufficient notice and lack of notice to directors proposed for removal. A recent private placement transaction has increased the outstanding ordinary shares. Shareholders are advised to seek legal advice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
News
YS Biopharma Announces US$40 Million Private Placement Financing
Rhea-AI Summary
YS Biopharma Co., Ltd. announced a $40 million private placement of 95,269,762 ordinary shares at $0.41986 per share, strengthening its balance sheet and supporting business growth. The transaction was exempt from registration requirements under the Securities Act of 1933 and followed the dismissal of an injunction order.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
News
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
Rhea-AI Summary
YS Biopharma Co., Ltd. announced the convening of an extraordinary general meeting of shareholders to remove six current members of the board of directors and elect four new directors. The meeting will be held on February 16, 2024, with Yi Zhang, the founder of YS Biopharma, being the Convening Shareholder. Shareholders of record as of February 8, 2024, are entitled to vote at the EGM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
News
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) reported unaudited financial results for the first half of fiscal year 2024, with Dr. David Shao, the Director, President, and CEO, addressing the lingering impact of inventory issues from COVID-related disruptions at their YSJA rabies vaccine manufacturing facilities. However, operational enhancements have been made to overcome setbacks, resulting in a return to normal vaccine production and an improvement in inventory levels. The company expects a 50% increase in YSJA rabies vaccine revenues in the third quarter of fiscal year 2024. Product candidates are advancing in development, signaling optimism for the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
earnings
News
YS Biopharma Announces Changes to its Board Committees
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) announced the appointment of Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee. Ms. Yu brings extensive experience in the healthcare and finance sectors, having previously held positions at Oceanpine Capital, China Renaissance Group, and Gerson Lehman Group. Her educational background includes degrees from Guangdong Pharmaceutical University, the University of Missouri School of Medicine, and the University of Chicago Booth School of Business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
none
-
News
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) responds to unauthorized press release, clarifies board composition and meeting misinformation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
-
News
YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) will hold an extraordinary general meeting of shareholders on December 28, 2023, to vote on the removal and appointment of directors. The record date for shareholders entitled to receive notice is December 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
News
DELETED: YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023
Rhea-AI Summary
No press release available for the given story.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
Stock YS logo
YS Biopharma Co Ltd

Nasdaq:YS

YS Rankings

#3974 Ranked by Market Cap
#5515 Ranked by Stock Gains
N/A Ranked by Dividends

YS Stock Data

161.96M
17.10M
81.43%
4.98%
0.05%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
China
Beijing